Drug Trial Radar · NCT02991118
Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk
Last checked: Nov 20, 2026Latest source record: Apr 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
779
Actual
Start
Nov 18, 2016
Primary completion
Aug 22, 2018
Study completion Aug 22, 2018
Sponsor
- Lead sponsor
- Esperion Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 13, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to see if bemedoic acid (ETC-1002) is effective versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol not adequately controlled by their current therapy.
Conditions
- Hypercholesterolemia
- Atherosclerotic Cardiovascular Disease
Interventions
bempedoic acidDrug
bempedoic acid 180 mg tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
placeboDrug
Matching placebo tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C)Time frame: Baseline; Week 12
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Clearwater, Florida
Site not named
Georgetown, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.